Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Recruiting 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Breast 1

Conditions

Breast Neoplasms 71Neoplasm Metastasis 26Stomach Neoplasms 12Carcinoma, Non-Small-Cell Lung 11Colorectal Neoplasms 10Neoplasms 8Brain Neoplasms 8Adenocarcinoma 6Triple Negative Breast Neoplasms 5Pancreatic Neoplasms 4Ovarian Neoplasms 4Esophageal Neoplasms 4Endometrial Neoplasms 4Salivary Gland Neoplasms 3Recurrence 3HER2-positive Breast Cancer 3Advanced Solid Tumor 3Sarcoma 2Prostatic Neoplasms 2Neoplasm, Residual 2Meningeal Carcinomatosis 2Melanoma 2HER2-positive Gastric Cancer 2Gastrointestinal Neoplasms 2Colonic Neoplasms 2Carcinoma, Renal Cell 2Breast Cancer With Brain Metastasis 2Advanced Breast Cancer 2Adenocarcinoma Of Esophagus 2Vulvar Neoplasms 1

Interventions

trastuzumab deruxtecan 1Injections 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Unresectable Locally Recurrent Breast Cancer × trastuzumab deruxtecan × Clear all
NCT07497386 2026-05-11

A Trial of Trastuzumab Rezetecan in Unresectable Locally Recurrent/Metastatic Breast Cancer

Jiangsu HengRui Medicine Co., Ltd.

Phase 2 Recruiting
150 enrolled
Breast

Unresectable Locally Recurrent Breast Cancer

Data powered by HemOnc (CC BY 4.0) Colophon âš¡